Premium
Recombinant polyclonal antibodies for cancer therapy
Author(s) -
Sharon Jacqueline,
Liebman Meredith A.,
Williams Brent R.
Publication year - 2005
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20536
Subject(s) - polyclonal antibodies , monoclonal antibody , antibody , recombinant dna , monoclonal , cancer , hybridoma technology , cancer cell , phage display , cancer research , biology , microbiology and biotechnology , immunology , genetics , gene
Although monoclonal antibodies are increasingly used for cancer therapy, remissions are only temporary due to emergence of tumor cell escape variants that are no longer affected by the antibody. The emergence of escape variants could be minimized by multi‐targeting of tumor cells with polyclonal antibodies, which would also be more efficient than monoclonal antibodies at mediating effector functions for target destruction. A technology for generating recombinant polyclonal antibodies for cancer therapy has been developed based on the construction and selection of tumor‐reactive Fab phage display libraries. The selected Fabs are mass‐converted to full‐length polyclonal antibody libraries (PCALs) of any isotype and any species. Prototypic PCALs generated against human colorectal cancer cell lines showed that libraries of diverse recombinant antibodies, enriched for reactivity to the cancer cells compared to normal human cells, can be obtained. The success of recombinant polyclonal antibodies as cancer therapeutics will depend on the ability to generate, characterize, and mass‐produce PCALs with high ratios of cancer‐to‐normal reactivities that cross‐react with many cancers of the same type. © 2005 Wiley‐Liss, Inc.